Risk Factorb | Death during admission | No death during admission | OR (95% CI) | P value |
---|---|---|---|---|
N | 36 | 253 | Â | Â |
Demographics | ||||
Male | 22 (61) | 176 (70) | Â | 0.31 |
Race/Ethnicity | Â | Â | Â | 0.46 |
   Black | 22 (61) | 145 (50) |  |  |
   Hispanic | 9 (25) | 44 (15) |  |  |
   Other race | 2 (6) | 23 (8) |  |  |
   White | 3 (8) | 41 (14) |  |  |
Age | 51.6 (15.8) | 47.6 (15.3) | Â | 0.15 |
Microbiological Factors | ||||
Epidemiologic risk | Â | Â | Â | 0.76 |
   Community associated | 11 (31) | 69 (27) |  |  |
   Healthcare associated | 8 (22) | 71 (28) |  |  |
   Hospital onset | 17 (47) | 113 (45) |  |  |
MRSA | 17 (47) | 103 (41) | Â | 0.46 |
Urine culture positive | 14 (39) | 43 (17) | 3.11 (1.47 - 6.55) | 0.002 |
Clinical Factors | ||||
HIV | 6 (17) | 28 (11) | Â | 0.32 |
Bladder catheter | 19 (53) | 86 (34) | 2.17 (1.07 - 4.39) | 0.03 |
Charlson score | 2.84 | 2.04 | Â | 0.22 |
Hemodialysis | 1 (3) | 26 (11) | 0.24 (0.03 - 1.90) | 0.15 |
Immunosuppressed | 8 (22) | 45 (18) | Â | 0.52 |
Urological surgery | 0 (0) | 13 (5) | Â | 0.16 |
DM | 13 (36) | 70 (28) | Â | 0.30 |
IVDA | 4 (11) | 42 (17) | Â | 0.40 |
Prosthetic device | 3 (8) | 63 (25) | 0.27 (0.08-0.92) | 0.03 |
Alcoholism | 7 (19) | 40 (16) | Â | 0.58 |
ID consult or managementc | 18 (50) | 128 (60) | Â | 0.25 |
Line/phlebitis | 2 (6) | 56 (22) | 0.21 (0.05-0.89) | 0.02 |
Skin soft tissue infection | 7 (19) | 50 (20) | Â | 0.96 |
Bone/joint infection | 2 (6) | 25 (25) | Â | 0.40 |
Pulmonary infection | 6 (17) | 35 (14) | Â | 0.65 |
GU infection | 0 (0) | 22 (9) | Â | 0.05 |
Incubation Period | 26.8 (67.4) | 12.4 (24.0) | Â | 0.21 |
Outcome | ||||
Fever days | 2.7 (4.8) | 3.7 (5.0) | Â | 0.11 |
Time to effective therapy | 1.06 (2.6) days | 1.8 (3.7) days | Â | 0.12 |
Length of stay after culture | 10.1 (11.3) days | 13.5 (14.1) days | Â | 0.17 |